Please assess the completion status of the following clinical trial:

Trial Title: Methods to Detect Liver Fibrosis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria~Group 1:~1. Healthy subjects with no known or suspected liver disease~2. Age 8 - 21 years~Groups 2 and 3:~1. Biopsy confirmed liver fibrosis (F1/F2 Group 2, F3/F4 Group 3)~2. Age 8 - 21 years~Group 4:~1. Biopsy confirmed hepatic steatosis AND biopsy confirmed liver fibrosis (any stage)~2. Age 8 - 21 years~Exclusion Criteria~All subjects:~1. Subjects \<8 years of age and \>21 years of age.~2. BMI \> 35 kg/m2~3. Subjects deemed to possibly require sedation to undergo MR imaging~4. Inability to lie still for 90 minutes~5. Routine exclusions to MRI - e.g., implanted hardware~6. Pregnancy (verbal pregnancy screens - per standard practice in Radiology - will be administered to all female participants of child-bearing age at the time of enrollment and again immediately prior to imaging)~7. Prior history of liver transplantation~Group 1~1. ALT ≥30 U/L~2. Clinical history or lab/biopsy results suggestive of the presence of liver disease including: steatosis, fibrosis, inflammation, tumor, etc.~Group 2 and 3~1. Diagnosis of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis~2. Biopsy \>6 months prior to research MRI examination~3. Initiation of any medications (e.g. steroids, immunosuppressants, antivirals) or procedures (e.g. Kasai portoenterostomy) to treat the liver disease during the time between liver biopsy and study visit~Group 4~1. Biopsy \>6 months prior to research MRI examination~2. Hepatic fat fraction \>5%~3. Substantial weight loss (\>10% of weight at time of biopsy) during the time between biopsy and study visit~4. Initiation of any medications to treat NAFLD (e.g. vitamin E) during the time between biopsy and study visit

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 21 Years
- Healthy Volunteers: t

Study Arms:
- Health/Normal Controls (Type: ACTIVE_COMPARATOR): Health/normal control subjects will undergo MRI using several different imaging sequences (MR Elastography, T1 mapping, T2 mapping, T1 rho, and magnetization transfer) designed to detect and quantify hepatic fibrosis.
- F1/F2 fibrosis (Type: ACTIVE_COMPARATOR): Type 1 and 2 liver fibrosis subjects will undergo MRI using several different imaging sequences (MR Elastography, T1 mapping, T2 mapping, T1 rho, and magnetization transfer) designed to detect and quantify hepatic fibrosis.
- F3/F4 fibrosis (Type: ACTIVE_COMPARATOR): Type 2 and 3 liver fibrosis subjects will undergo MRI using several different imaging sequences (MR Elastography, T1 mapping, T2 mapping, T1 rho, and magnetization transfer) designed to detect and quantify hepatic fibrosis.
- Hepatic steatosis with fibrosis (Type: ACTIVE_COMPARATOR): Hepatic steatosis with liver fibrosis subjects will undergo MRI using several different imaging sequences (MR Elastography, T1 mapping, T2 mapping, T1 rho, and magnetization transfer) designed to detect and quantify hepatic fibrosis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues